+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
ID07198841

Phase II Study of IBI351 Plus Cetuximab Beta for Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With KRAS G12C Mutation

Led by Guangdong Association of Clinical Trials · Updated on 2026-03-11

48

Participants Needed

7

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the combination of IBI351 and cetuximab for treating adults with untreated, locally advanced or metastatic non-small cell lung cancer NSCLC that has the KRAS G12C mutation. This Phase II, single-arm, multicenter study seeks to assess the safety and effectiveness of this treatment in patients who have not received prior systemic therapy for this lung cancer subtype. The goal is to measure tumor response using established criteria and monitor patient survival and disease progression. Participants will receive oral IBI351 at a dose of 600 mg twice daily, combined with an intravenous infusion of cetuximab at 500 mgm every two weeks. Each treatment cycle is two weeks long, and therapy continues until the cancer worsens or unacceptable side effects occur. Dosage adjustments may be made based on patient tolerance. This study does not include a comparison group and follows patients through their treatment course. Throughout the study, patients will undergo regular assessments including tumor measurements using RECIST version 1.1 criteria, safety evaluations, and monitoring of disease control and survival outcomes for up to two years. Researchers will track objective response rate as the primary outcome, along with secondary outcomes like progression-free survival, time to response, overall survival, and adverse events. Participation involves ongoing clinical evaluations and laboratory testing to ensure safety and measure treatment impact.

CONDITIONS

Brief Title

IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

Research Team

Q

Qing Zhou, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here